ADGRE5 and prostate carcinoma: CD97/ADGRE5, a close homolog of EMR2, was reported to heterodimerize with the lysophosphatidic acid (LPA) receptor 1 and signal via Gα12/13 to induce LPA-dependent Rho and ERK activation in prostate cancer cells (39).